IL2 and melanoma: Niethammer et al. (2001) found that the obviously up-regulation in expression of CD48 and B7.1 on antigen-presenting cells provided further evidence for the effectiveness of the targeted Interleukin 2 therapy enhancing the immune response induced by an autologous oral DNA vaccine against murine melanoma.